Eli Lilly and Company (LLY)
| Market Cap | 671.90B |
| Revenue (ttm) | 40.86B |
| Net Income (ttm) | 8.37B |
| Shares Out | 900.43M |
| EPS (ttm) | 9.25 |
| PE Ratio | 80.68 |
| Forward PE | 33.68 |
| Dividend | $5.20 (0.70%) |
| Ex-Dividend Date | Nov 15, 2024 |
| Volume | 6,383,606 |
| Open | 775.19 |
| Previous Close | 784.93 |
| Day's Range | 744.20 - 776.74 |
| 52-Week Range | 561.65 - 972.53 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 962.05 (+28.93%) |
| Earnings Date | Oct 30, 2024 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]
Financial Performance
In 2023, Eli Lilly's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $962.05, which is an increase of 28.93% from the latest price.
News
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De...
Three-Stock Lunch: Eli Lilly, Transdigm, & Nvidia
Lee Munson, president and CIO at Portfolio Wealth Advisors, joins CNBC's ‘Power Lunch' to discuss outlooks on three stocks: Eli Lilly, Transdigm, and Nvidia.
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
Shares in some of America's largest drug manufacturers tumbled yesterday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his pick for secretary of the Department of Health and Hu...
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme...
RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr....
Lilly Sues U.S. to Change Hospital Drug Discount Payments
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain hospitals.
Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program
Eli Lilly (LLY) became the second drugmaker in recent days to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facili...
Lilly sues US agency over blocking of drug-rebate program
Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking the company's plan to change the way it offers drug discounts to hospitals.
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
On Wednesday, Eli Lilly And Co LLY released detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide.
5 Healthcare Stocks to Buy in a Beaten-Up Sector
It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.
Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
SURMOUNT-1 results show a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three years Results suggest one new case of diabetes c...
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections.
Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board
CINCINNATI--(BUSINESS WIRE)--Asha Therapeutics Selected as Recipient of ALS Association's Barnett Grant, Disarm Therapeutics' founders Drs. Milbrandt & DiAntonio to join Asha SAB.
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve's interest rate cuts in September.
Why most healthcare stocks are falling with Trump's win, with some exceptions
Investors are worried about what a Trump administration means for hospital operators and vaccine makers, but are optimistic about the fate of Medicare Advantage plan providers.
Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
INDIANAPOLIS , Nov. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase ...
Americans seeking Eli Lilly and Novo Nordisk's weight-loss drugs turn to compounded market
Americans are still eagerly seeking prescriptions for Eli Lilly and Novo Nordisk's weight-loss and diabetes drugs but cannot always fill them because of supply issues and insurance hurdles, according ...
This Pharma Stock Is Soaring 21%. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo.
Viking said that an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body weight in four weeks.
KFSHRC & Lilly Collaborate in Alzheimer's Early Detection
RIYADH, Saudi Arabia, Nov. 03, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia signed an MoU today to improve Alzheimer's patient care. T...
Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium
INDIANAPOLIS , Nov. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader ...
Three Buys and a Bail: Microsoft, Eli Lilly, Peloton, and Snap
Gina Sanchez, Lido Advisors chief market strategist, joins CNBC's 'The Exchange' to discuss these stocks: Microsoft, Eli Lilly, Peloton, and Snap.
Market Movers: 2 Top Dividend Stocks I'm Watching No Matter Who Wins
With the upcoming election sparking volatility, I'm sharing two dividend stocks on my radar. These picks offer reliable growth potential, no matter the political outcome. Each stock has a solid track ...
Eli Lilly Earnings Have Wall Street Jittery on Zepbound Sales. What Comes Next.
Sales of Zepbound and Mounjaro both missed Wall Street estimates by significant margin.
MSFT, GOOGL "Overpenalized" & LLY, CMG "Overvalued"
According to Dave Sekera with @morningstar, the markets are reacting too harshly to Meta Platforms (META) and Microsoft's (MSFT) earnings. He says both companies are "undervalued" when using Morningst...
Buy, Sell, Or Hold LLY Stock At $850?
Eli Lilly stock (NYSE: LLY) fell over 6% on Wednesday, October 30, after it posted downbeat results. The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below ...